FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 789 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... January 16, 2024 Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... October 9, 2020 The Taylor Family Foundation gives £2.1m to support head and neck... December 12, 2022 Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome October 9, 2020 Load more HOT NEWS Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early... EMA Recommends Extension of Therapeutic Indications for Pembrolizumab England: Smoking responsible for twice as many cancers in most deprived... EMA Recommends Extension of Indications for Enzalutamide
